6533b7dafe1ef96bd126e215

RESEARCH PRODUCT

Differential expression of the tumor suppressor A-kinase anchor protein 12 in human diffuse and pilocytic astrocytomas is regulated by promoter methylation

Lea GeiselhartPerikles SimonChristoph PlassPeter SchirmacherRichard MeyermannMichael WellerWolfgang WickCéline DutruelCornelia ZachskornDavid CapperDavid CapperPatrick N. HarterMarcus RennerBenito CamposPeter SchmezerWilko WeichertMonika Nadja VogelMichel MittelbronnChristopher R. SchmidtBenjamin GoeppertJens SchittenhelmJenny ZinkeOdilia Popanda

subject

AdultMalePathologymedicine.medical_specialtyAdolescent2804 Cellular and Molecular NeuroscienceA Kinase Anchor ProteinsCell Cycle Proteins610 Medicine & healthAstrocytomaBiologyPathology and Forensic MedicineCellular and Molecular NeuroscienceGliomamedicineHumansChildPromoter Regions GeneticneoplasmsAgedAged 80 and overRegulation of gene expressionPilocytic astrocytomaBrain NeoplasmsInfantAstrocytomaGeneral MedicineMethylationDNA MethylationMiddle AgedAKAP12medicine.diseaseUp-Regulationnervous system diseases10040 Clinic for NeurologyGene Expression Regulation Neoplastic2734 Pathology and Forensic Medicine2728 Neurology (clinical)nervous systemNeurologyChild Preschool2808 NeurologyDNA methylationCancer researchImmunohistochemistryFemaleNeurology (clinical)Neoplasm Grading

description

The scaffold protein A-kinase anchor protein 12 (AKAP12) exerts tumor suppressor activity and is downregulated in several tumor entities. We characterized AKAP12 expression and regulation in astrocytomas, including pilocytic and diffusely infiltrating astrocytomas. We examined 194 human gliomas and 23 normal brain white matter samples by immunohistochemistry or immunoblotting for AKAP12 expression. We further performed quantitative methylation analysis of the AKAP12 promoter by MassARRAY® of normal brain, World Health Organization (WHO) grade I to IV astrocytomas, and glioma cell lines. Our results show that AKAP12 is expressed in a perivascular distribution in normal CNS, strongly upregulated in tumor cells in pilocytic astrocytomas, and weakly expressed in diffuse astrocytomas of WHO grade II to IV. Methylation analyses revealed specific hypermethylation of AKAP12α promoter in WHO grade II to IV astrocytomas. Restoration experiments using 5-aza-2'-deoxycytidine in primary glioblastoma cells decreased AKAP12α promoter methylation and markedly increased AKAP12α mRNA levels. In summary, we demonstrate that AKAP12 is differentially expressed in human astrocytomas showing high expression in pilocytic but low expression in diffuse astrocytomas of all WHO-grades. Our results further indicate that epigenetic mechanisms are involved in silencing AKAP12 in diffuse astrocytomas; however, a tumor suppressive role of AKAP12 in distinct astrocytoma subtypes remains to be determined.

10.5167/uzh-85419https://doi.org/10.5167/uzh-85419